文献速递关节外科

Otto Aufranc奖:含碘产品在标注碘过敏的全关节置换患者中安全

The Otto Aufranc Award: Iodine-Containing Products Are Safe in Allergy-Labeled Patients Undergoing Total Joint Arthroplasty: A Prospective Observational Study.
PubMed 文献 · J Arthroplasty · 2026-04-21

这项前瞻性观察研究纳入2024年7月至2025年10月接受初次全关节置换术且标注碘过敏的37例患者,按标准流程使用聚维酮碘鼻腔去定植、含碘手术贴膜和稀释聚维酮碘冲洗。围手术期未观察到任何过敏反应,提示含碘产品在这类患者中可安全使用。

要点

  • 标注碘过敏的全关节置换患者围手术期使用含碘产品未发生过敏反应。
  • 研究共纳入37例碘过敏标注患者,占同期1211例初次全关节置换的3.1%。
  • 结果挑战常规避免含碘产品的做法,支持标准化消毒流程以降低假体周围感染。

核心结论

  • 含碘产品在标注碘过敏的全关节置换患者中安全,本研究未观察到过敏反应。

研究设计与样本

  • 前瞻性观察研究,纳入2024年7月至2025年10月接受初次全关节置换且标注碘过敏的患者37例。

主要发现

  • 37例患者中5例(13.5%)为皮肤试验确认过敏,25例(67.6%)对造影剂过敏,4例(10.8%)对聚维酮碘过敏,5例(13.5%)合并贝类过敏。
  • 患者报告的平均过敏持续时间为27.9年。
  • 问卷显示患者报告恶心呕吐(78.4%)、轻度瘙痒(83.8%)、皮疹(29.9%)、严重瘙痒(62.2%)、喘息(78.4%)、呼吸困难(59.5%)和肿胀(89.2%),70%报告一种以上反应。
  • 围手术期使用含碘产品后,研究纳入的患者未发生过敏反应。

关键数值与推荐

  • 标准手术流程包括聚维酮碘鼻腔去定植、使用含碘手术贴膜和术中稀释聚维酮碘冲洗,未偏离方案。
  • 主要终点为整个住院期间任何围手术期过敏反应。

临床怎么用

  • 对于标注碘过敏的全关节置换患者,不应常规避免含碘消毒产品,可按标准化流程使用以降低假体周围感染和手术部位感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Povidone-iodine (PVP-I) and iodophor-impregnated drapes are essential antiseptic measures for total joint arthroplasty (TJA). However, many surgical settings may prevent surgeons from using iodine-containing products when a patient has a documented allergy, even if the cross-reactivity is unproven or based on distant self-reported history. As iodine has been a well-accepted measure to reduce periprosthetic joint infections and surgical site infection, this study sought to prospectively evaluate the safety of using iodine-containing products (iodophors) in iodine allergy labeled patients undergoing TJA. METHODS: In this prospective observational study, patients with documented iodine allergy undergoing primary TJA from July 2024 to October 2025 were enrolled. Patients completed a preoperative questionnaire including the source, duration, and type of allergic reaction. The standard-of-care operative workflow, including PVP-I nasal decolonization, use of iodophor-impregnated adhesive drape, and intraoperative lavage with diluted PVP-I was followed without deviation from protocol. The primary end point was any perioperative allergic reaction throughout the stay. RESULTS: Of the 1,211 primary TJA performed during this time, there were 37 (3.1%) iodine allergy labeled patients. There were five (13.5%) patients who had skin test-confirmed allergies, 25 (67.6%) patients who were allergic to contrast media, four (10.8%) patients who were allergic to betadine, and five (13.5%) patients who had a concurrent shellfish allergy. The mean reported allergy duration was 27.9 years. Questionnaire results showed patients reporting reactions of nausea and vomiting (78.4%), mild itching (83.8%), rash (29.9%), severe itching (62.2%), wheezing (78.4%), difficulty breathing (59.5%), and swelling (89.2%). Most patients (70%) reported more than one reaction. However, the enrolled patients in this study had no allergic reactions to the iodophors used in the perioperative period. CONCLUSIONS: Iodophors are safe in iodine-allergic patients undergoing TJA. No allergic reactions were observed in this study. These findings challenge routine iodophor avoidance, supporting standardized antiseptic protocols to minimize periprosthetic joint infection.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Samineni AV, Cruz-Ossa N, Reddy GB, et al. The Otto Aufranc Award: Iodine-Containing Products Are Safe in Allergy-Labeled Patients Undergoing Total Joint Arthroplasty: A Prospective Observational Study. J Arthroplasty. 2026. PMID: 42025856. doi:10.1016/j.arth.2026.04.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。